Recombinetics is at the forefront of gene editing technologies, focusing on applications in animal agriculture, biomedical research, and regenerative medicine. The company utilizes a proprietary gene editing platform that allows for precise modifications to animal DNA, unlocking new traits that can enhance health, welfare, and productivity. This technology is particularly impactful in agriculture, where it enables the development of healthier livestock with improved traits, reducing the reliance on antibiotics and promoting environmental sustainability. Additionally, Recombinetics offers preclinical services that utilize custom gene-edited animal models, which can help streamline the research and development of new therapies while minimizing the use of nonhuman primates.

In the biomedical field, Recombinetics is advancing precision medicine through its subsidiaries, such as Sarxion Biologics, which focuses on engineering materials for regenerative medicine, and Therillume, which targets neuro-oncology therapeutics. The company’s gene editing capabilities facilitate the creation of advanced animal models for studying human diseases, thereby enhancing the development of safer and more effective treatments. By adhering to strict regulatory standards and ensuring the humane treatment of animals, Recombinetics is committed to responsibly harnessing the power of gene editing to improve human health and agricultural practices.

United States

Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.

Led by a team of expert geneticists, genome engineers, and reproductive physiologists, the company is headquartered in St. Paul, Minnesota.

Recombinetics

Company Details